{"id":"NCT03391882","sponsor":"Sumitomo Pharma America, Inc.","briefTitle":"A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)","officialTitle":"An Open-Label, Randomized, Crossover Trial Utilizing a Single-Blinded Rater to Evaluate APL-130277 Compared to Subcutaneous Apomorphine in Levodopa Responsive Subjects With Parkinson's Disease Complicated by Motor Fluctuations","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-19","primaryCompletion":"2021-08-11","completion":"2021-08-11","firstPosted":"2018-01-05","resultsPosted":"2022-12-16","lastUpdate":"2022-12-16"},"enrollment":113,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Motor OFF Episodes Associated With Parkinson's Disease"],"interventions":[{"type":"DRUG","name":"APL-130277","otherNames":["Apomorphine Hydrochloride"]},{"type":"DRUG","name":"subcutaneous apomorphine","otherNames":["APO-goÂ®"]}],"arms":[{"label":"APL-130277","type":"EXPERIMENTAL"},{"label":"subcutaneous apomorphine","type":"ACTIVE_COMPARATOR"}],"summary":"A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations (\"OFF\" Episodes) compared to an approved drug used to treat people with Parkinson's Disease complicated by motor fluctuations (\"OFF\" Episodes)","primaryOutcome":{"measure":"Change From Pre-dose to 90 Mins. Post-dose in Movement Disorders Society Unified Parkinson's Disease Rating Scale Part III Score After 4 Weeks of Dosing in Each Crossover Period (Assessed by the Blinded-rater In-clinic at Visit 3 and Visit 6 of PART B).","timeFrame":"Pre-dose to 90 minutes post-dose at Week 4 of each treatment period (Visit 3 and 6)","effectByArm":[{"arm":"SC (Subcutaneous Apomorphine)","deltaMin":-13.78,"sd":null},{"arm":"APL (APL-130277)","deltaMin":-13.55,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.8944"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["Austria","France","Germany","Italy","Spain","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":102},"commonTop":["Nausea","Dyskinesia","Somnolence","Fatigue","Injection site haematoma"]}}